ENA Respiratory raises $3.0M Grant (Australia, September 2026)
Australian biotech ENA Respiratory, whose INNA-051 nasal spray targets respiratory viruses, has been granted $2.98 million via the Biointelect Venturer program to fund a trial in adults with asthma.
Under Brandon Capital portfolio ·leads this story in the feed